Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2004-10-15
2008-10-14
Mondesi, Robert B. (Department: 1652)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
07435717
ABSTRACT:
The invention provides methods and formulations for treating and preventing acute coronary syndromes. The methods of the instant invention provide safe and effective doses of an Apolipoprotein A-I Milano:phospholipid complex to reduce and stabilize atherosclerotic plaque. Pharmaceutical formulations of the Apo A-I Milano:phospholipid complexes are also provided.
REFERENCES:
patent: 5876968 (1999-02-01), Sirtori et al.
patent: 6617134 (2003-09-01), Sirtori et al.
patent: 2003/0109442 (2003-06-01), Bisgaier et al.
Cole et al., Method-dependent changes in “HDL-cholesterol” with recombinant apolipoprotein A-l(Milano) infusion in healthy volunteers, Clin Chem. 2002, vol. 48. No. 4, pp. 680-681.
Rioufol, G., et al, “Multiple Atherosclerotic Plaque Rupture in Acute Coronary Syndrome; A Three-Vessel Intravascular Ultrasound Study”, Circulation, 2002; 106; pp. 804-808.
Timmis, Adam, “Plaque Stabilisation in Acute Coronary Syndromes: Clinical Considerations”, Heart; 2003; 89; pp. 1268-1272.
Franceschini, G., et al, “A-l Milano Apoprotein; Decreased High Density Lipoprotein Cholesterol Levels With Significant Lipoprotein Modifications and Without Clinical Atherosclerosis in an Italian Family”, J. Clin. Invest., 1980; 66; pp. 892-900.
Weisgraber, K., et al, “Apolipoprotein A-l Milano—Detection of Normal A-l in Affected Subjects and Evidence for a Cysteine for Arginine Substitution in the Variant A-l*”, The Journal of Biological Chemistry, 1983; 258; 4; pp. 2508-2513.
Franceschini, G., et al, “Apolipoprotein A-l Milano; Correlation between High Density Lipoprotein Subclass Distribution and Triglyceridemia”, Arteriosclerosis; 1987; 7; pp. 426-435.
Ameli, S., et al, “Recombinant Apolipoprotein A-l Milano Reduces Intimal Thickening After Balloon Injury in Hypercholesterolemic Rabbits”, Circualtion, 1994; 90; pp. 1935-1941.
Shah, P., et al, “Effects of Recombinant Apolipoprotein A-l Milano on Aortic Atherosclerosis in Apolipoprotein E-Deficient Mice”, Circulation, 1998; 97; pp. 780-785.
Shah, P., et al, “High-Dose Recombinant Apolipoprotein A-l Milano Mobilizes Tissue Cholesterol and Rapidly Reduces Plaque Lipid and Macrophage Content in Apolipoprotein E-Deficient Mice—Potential Implications for Acute Plaque Stabilization”, Circulation, 2001; 103; pp. 3047-3050.
Li, D., et al, “Inhibition of Arterial Thrombus Formation by ApoAl Milano”, Arterloscler Thromb Vasc Biol., 1999; 19; pp. 378-383.
Newton, R., et al, “HDL therapy for the acute treatment of atherosclerosis”, Atherosclerosis Supplements, 2002; 3; pp. 31-38.
Chiesa, G., et al, “Recombinant Apolipoprotein A-l Milano Infusion Into Rabbit Carotid Artery Rapidly Removes Lipid From Fatty Streaks”, Circ Res., 2002; 90; pp. 974-980.
Soma, M., et al, “Recombinant Apolipoprotein A-l Milano Dimer Inhibits Carotid Intimal Thickening Induced by Perivascular Manipulation in Rabbits”, Cir. Res., 76, 1995; pp. 405-411.
Qiao, J., et al., Pathology of Atheromatous Lesions in Inbred and Genetically Engineered Mice,Arteriosclerosis and Thrombosis, vol. 14(9):1480-1497, 1994.
Warnick, G., et al., Evolution of Methods for Measurement of HDL-cholesterol: From Ultracentrifugation to Homogeneous Assays,Clinical Chemistry, vol. 47(9): 1579-1596, 2001.
Sviridov, et al., Journal of Lipid Research, vol. 43, pp. 1283-1292 (2002).
Bisgaier Charles L.
Hartman Daniel
Johansson Jan
Lalwani Narendra D.
Rodrigueza Wendi V.
Benson Gregg C.
Mondesi Robert B.
Pfizer Inc.
Slepchuk, Jr. Nicholas I.
LandOfFree
Pharmaceutical formulations, methods, and dosing regimens... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical formulations, methods, and dosing regimens..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical formulations, methods, and dosing regimens... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4006167